Literature DB >> 3292793

Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus.

E P Lillehoj1, F H Salazar, R J Mervis, M G Raum, H W Chan, N Ahmad, S Venkatesan.   

Abstract

We have purified a 10,774-dalton protein from human immunodeficiency virus (HIV) type 1 that is encoded in the protease domain of the pol open reading frame (ORF). Radiochemical amino acid microsequencing identified 12 amino acids from the stretch of 39 N-terminal residues of this protein, beginning with a PQITLW sequence at position 69 of the pol ORF. Radiosequencing of selected tryptic peptides of the protein identified 11 additional residues (Leu-9 and Val-2) in six peptides encompassing the entire molecule of 99 residues. A protein of similar size and identical N-terminal sequence (determined through the first 39 residues) was present among the processed HIV pol gene products in Escherichia coli which expressed the entire HIV pol ORF. The C terminus of both the viral and E. coli-expressed proteins was inferred to be contiguous with the N terminus of the p64-p51 reverse transcriptase on the basis of tryptic mapping and specific immunoreactivity with an antiserum against a dodecapeptide located upstream of the reverse transcriptase. Thus, the initial processing of the pol precursor that generates the native protease is apparently preserved across phylogenetic barriers. Although the purified viral protease lacked measurable proteolytic activity, the bacterial extracts were capable of processing an HIV gag precursor protein synthesized in E. coli.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3292793      PMCID: PMC253749     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Biochemical properties of p15-associated protease in an avian RNA tumor virus.

Authors:  K J Dittmar; K Moelling
Journal:  J Virol       Date:  1978-10       Impact factor: 5.103

2.  Expression of the Rous sarcoma virus pol gene by ribosomal frameshifting.

Authors:  T Jacks; H E Varmus
Journal:  Science       Date:  1985-12-13       Impact factor: 47.728

3.  Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

Authors:  F di Marzo Veronese; T D Copeland; A L DeVico; R Rahman; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

4.  In vitro cleavage of avian retrovirus gag proteins by viral protease p15.

Authors:  V M Vogt; A Wight; R Eisenman
Journal:  Virology       Date:  1979-10-15       Impact factor: 3.616

5.  The gag and pol genes of bovine leukemia virus: nucleotide sequence and analysis.

Authors:  N R Rice; R M Stephens; A Burny; R V Gilden
Journal:  Virology       Date:  1985-04-30       Impact factor: 3.616

6.  Structural definition of a family of Ld-like molecules distributed among four of seven haplotypes compared.

Authors:  E P Lillehoj; N B Myers; D R Lee; T H Hansen; J E Coligan
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

7.  A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins.

Authors:  S Crawford; S P Goff
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

8.  Radiochemical sequence analysis of biosynthetically labeled proteins.

Authors:  J E Coligan; F T Gates; E S Kimball; W L Maloy
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

9.  Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients.

Authors:  W G Robey; B Safai; S Oroszlan; L O Arthur; M A Gonda; R C Gallo; P J Fischinger
Journal:  Science       Date:  1985-05-03       Impact factor: 47.728

10.  Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon.

Authors:  Y Yoshinaka; I Katoh; T D Copeland; S Oroszlan
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

View more
  22 in total

1.  Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases.

Authors:  D D Loeb; C A Hutchison; M H Edgell; W G Farmerie; R Swanstrom
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles.

Authors:  A J Smith; M I Cho; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

3.  Identification of a uniquely immunodominant, cross-reacting site in the human immunodeficiency virus endonuclease protein.

Authors:  E Björling; G Utter; P Stålhandske; E Norrby; F Chiodi
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

Review 4.  Resistance to human immunodeficiency virus type 1 protease inhibitors.

Authors:  D Boden; M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

5.  Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.

Authors:  A Tanuri; A C Vicente; K Otsuki; C A Ramos; O C Ferreira; M Schechter; L M Janini; D Pieniazek; M A Rayfield
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

6.  Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication.

Authors:  A H Kaplan; M Manchester; T Smith; Y L Yang; R Swanstrom
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

7.  Differentiation of two bovine lentiviruses by a monoclonal antibody on the basis of epitope specificity.

Authors:  L Zheng; S Zhang; C Wood; S Kapil; G E Wilcox; T A Loughin; H C Minocha
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

8.  The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors.

Authors:  R J Mervis; N Ahmad; E P Lillehoj; M G Raum; F H Salazar; H W Chan; S Venkatesan
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

9.  Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles.

Authors:  A J Smith; N Srinivasakumar; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Immunological characterization of the gag gene products of bovine immunodeficiency virus.

Authors:  J K Battles; M Y Hu; L Rasmussen; G J Tobin; M A Gonda
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.